Availability of quality fixed-dose combinations for the treatment of tuberculosis: what can we learn from studying the World Health Organization's vaccine model?
METHODS
In efforts to promote the use of fixed-dose combinations (FDCs) for the treatment of tuberculosis (TB), the World Health Organization (WHO) and partners address the issue of quality assurance.


OBJECTIVE
To provide guidance for the development of strategies for quality assurance of FDCs.


METHODS
This review examines the WHO strategies for and experience with quality assurance and supply of vaccines.


RESULTS
Several elements in the strategies for quality assurance and supply of vaccines may be applicable for FDCs. At national level, the important strategies are to strengthen National Regulatory Authorities (NRA) and procurement systems and develop planning activities. Stressing quality assurance of FDCs in training activities for regulatory personnel and recommending that aid agencies require adherence to quality assurance policies as conditions for support would promote the implementation of quality assurance of FDCs at country level. At the global level, pre-qualification of manufacturers of FDCs should be explored as a mechanism to assure quality. The pre-qualification process should include evaluation of product files, initial testing for compliance and consistency of specifications, and site visits to producers and NRAs. The vaccine model defines criteria for reassessment that can be used for FDCs.
Blomberg
B
B
Department for Endemic Diseases Control, Prevention and Eradication, Communicable Diseases Cluster, World Health Organization, Geneva, Switzerland. blomberg@who.ch
Kitler
M E
ME
Milstien
J
J
Dellepiane
N
N
Fanning
A
A
Norval
P Y
PY
Spinaci
S
S
D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000592:standards* / Q000627:therapeutic use; D004338:Drug Combinations; D004345:Drug Industry / Q000592:standards; D004335:Drug and Narcotic Control; D006801:Humans; D011786:Quality Control; D014376:Tuberculosis / Q000188:drug therapy*; D014612:Vaccines / Q000592:standards*; D014944:World Health Organization
D000995:Antitubercular Agents; D004338:Drug Combinations; D014612:Vaccines